IBB News Alert Nasdaq Biotechnology Ishares (IBB) 303.35 01/01/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 303.35 $IBB

DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially
SA Editors - Seeking Alpha - Tue Dec 30, 6:05AM CST
Today we present the fifth piece in Seeking Alpha's Positioning for 2015 series. This year we have once again asked experts on a range of different asset classes and investing strategies to offer their vision for the coming year and beyond....
BIIB: 339.45 (-2.74), SPY: 205.54 (-2.06), PTLA: 28.32 (-0.24), PCYC: 122.26 (-0.32), GILD: 94.26 (-1.02), ACHN: 12.25 (-0.04), MRK: 56.79 (-0.86), EW: 127.38 (-1.89), IBB: 303.35 (-1.27), HQH: 31.49 (-0.04), REGN: 410.25 (+1.91), CELG: 111.86 (-1.68)

Analyzing The First Trust Health Care AlphaDEX ETF: How Did It Do It?
Stanford Chemist - at Seeking Alpha - Mon Dec 29, 10:40AM CST

PSCH: 59.76 (-0.45), IBB: 303.35 (-1.27), FXH: 60.29 (-0.57), XLV: 68.38 (-0.69)

TherapeuticsMD Is a Top Stock Under $10 for 2015: David Peltier
at The Street - Mon Dec 29, 9:35AM CST
Here's why the stock may blossom.
SON: 43.70 (-0.78), LMT: 192.57 (-2.86), GE: 25.27 (-0.30), TMP: 55.30 (-0.20), TXMD: 4.45 (+0.16), XBI: 186.46 (+0.92), IBB: 303.35 (-1.27), BTN: 4.14 (+0.10)

Biotech Weekly: Charts And Themes Present Mildly Bullish Outlook Into 2015
Daniel Ward - at Seeking Alpha - Mon Dec 29, 7:13AM CST

GILD: 94.26 (-1.02), XBI: 186.46 (+0.92), IBB: 303.35 (-1.27)

Pharma Stocks Could Be in Deep Trouble in 2015. Here's Why.
George Budwell, The Motley Fool - Motley Fool - Sun Dec 28, 12:05PM CST
Source: Flickr via user Derek Gavey. Pharmaceutical companies have had some of the best-performing stocks over the last couple of years thanks to an innovation boom that has produced a host of new game-changing drugs, from Gilead Sciences ' ...
ESRX: 84.67 (-1.08), GILD: 94.26 (-1.02), MRK: 56.79 (-0.86), IBB: 303.35 (-1.27), CVS: 96.31 (-1.22), ABBV: 65.44 (-0.86), GSK: 42.74 (-0.05), NVS: 92.66 (-0.55)

3 Stocks Poised for Eye-Popping Gains in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Dec 27, 6:27AM CST
Source: Flicker via 401kcalculator.org The stock market has been on fire since the start of 2012. Biotech companies, though, have posted particularly impressive gains, markedly outperforming the broader markets during this time period. The ...
OREX: 6.06 (+0.12), GILD: 94.26 (-1.02), VVUS: 2.88 (+0.10), IBB: 303.35 (-1.27), ABBV: 65.44 (-0.86), PRTA: 20.76 (+0.07), ARNA: 3.47 (+0.07)

Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers
Peter F. Way, CFA - Seeking Alpha - Wed Dec 24, 8:33AM CST
This is a market price forecast analysis It is not an analysis of medical technology, competition, or economics. We have limited competence in those areas. But we do have extensive experience in how market professionals have interpreted the likely...
ESRX: 84.67 (-1.08), GILD: 94.26 (-1.02), FBT: 102.02 (-0.42), BIB: 125.50 (-0.93), XBI: 186.46 (+0.92), IBB: 303.35 (-1.27), BBH: 115.38 (-0.56), ABBV: 65.44 (-0.86)

Why I Expect The Biotech Sell-Off To Continue Into 2015
Sammy Pollack - at Seeking Alpha - Wed Dec 24, 7:08AM CST

BIIB: 339.45 (-2.74), ESRX: 84.67 (-1.08), GILD: 94.26 (-1.02), IBB: 303.35 (-1.27), AMGN: 159.29 (-1.34), REGN: 410.25 (+1.91), CELG: 111.86 (-1.68)

Cramer's Mad Money - Navigator Holdings Has Been Unfairly Punished (12/23/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 24, 4:37AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday December 23. Navigator Holdings (NYSE: NVGS ) Has Been Unfairly Punished . Other stock mentioned: Transocean (NYSE: RIG ) With the surge in stocks, it...
RH: 96.01 (-0.75), GD: 137.62 (-2.01), LMT: 192.57 (-2.86), HON: 99.92 (-0.80), RTN: 108.17 (-1.71), NOC: 147.39 (-3.37), KMB: 115.54 (-1.81), XOM: 92.45 (-0.57), IBB: 303.35 (-1.27), VSAT: 63.03 (-0.05), NVGS: 21.06 (+0.94), JACK: 79.96 (-0.01), RIG: 18.33 (-0.35), Q: 58.87 (-0.82), COST: 141.75 (-1.74), WAG: 76.05 (-0.49), ETN: 67.96 (-0.81), MDSO: 47.75 (+0.10), DIS: 94.19 (-0.51), WFC: 54.82 (-0.60), PLKI: 56.27 (+0.29), BA: 129.98 (-1.85), DENN: 10.31 (+0.24), CBRL: 140.76 (+0.29), GILD: 94.26 (-1.02), CVX: 112.18 (-0.93)

Jim Cramer's 'Mad Money' Recap: Here Are 10 Stocks to Buy on Strong GDP Data
at The Street - Tue Dec 23, 7:26PM CST
Kimberly-Clark, Walgreen and Starbucks are among Cramer's winners on today's GDP number.
RH: 96.01 (-0.75), EYES: 10.26 (-0.50), ETN: 67.96 (-0.81), HON: 99.92 (-0.80), KMB: 115.54 (-1.81), IBB: 303.35 (-1.27), BMY: 59.03 (-0.36), PLKI: 56.27 (+0.29), MAR: 78.03 (-0.26), BA: 129.98 (-1.85), RRC: 53.45 (-0.20), VSAT: 63.03 (-0.05), SBUX: 82.05 (+0.26), NVGS: 21.06 (+0.94), COG: 29.61 (-0.16), GILD: 94.26 (-1.02), GWPH: 67.68 (+0.39), STI: 41.90 (-0.68), COST: 141.75 (-1.74), AI: 26.61 (-0.35), WAG: 76.05 (-0.49), PSEC: 8.26 (+0.02), EPD: 36.12 (-0.50)

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Rebound after Yesterday's 4.65% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 3:40PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $292.04 to a high of $309.94. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $306.37 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 303.35 (-1.27)

SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 4.65% Loss
Comtex SmarTrend(R) - Tue Dec 23, 3:39PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $292.04 to a high of $309.94. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of $306.37 on volume of 3.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 303.35 (-1.27)

Investors Should Stay Long Stocks as Market Continues Hitting Highs
at The Street - Tue Dec 23, 2:01PM CST
The CNBC 'Fast Money Halftime' trading panel knows there could be some risks in 2015.
AMZN: 310.35 (+0.05), IBB: 303.35 (-1.27), ALSN: 33.90 (-0.23), BAC: 17.89 (-0.24), TLT: 125.92 (+0.24), GOOG: 526.40 (-4.02), ESRX: 84.67 (-1.08), SPY: 205.54 (-2.06), QQQ: 103.25 (-1.07), GILD: 94.26 (-1.02), DIA: 177.88 (-1.58), APA: 62.67 (-0.30), ABBV: 65.44 (-0.86), BP: 38.12 (-0.24), GOOGL: 530.66 (-4.62), IWM: 119.62 (-0.72), XLE: 79.16 (-0.60)

Inside The 2 New Innovative Biotech ETFs From BioShares
Zacks Funds - Seeking Alpha - Tue Dec 23, 2:00PM CST
The biotechnology corner of the broader health care industry has been one of the best performing U.S. sectors this year despite some temporary glitches and rough trading in between. Encouraging industry trends, increasing merger and acquisition...
BBP: 26.12 (-0.06), BBC: 27.74 (+0.25), FBT: 102.02 (-0.42), XBI: 186.46 (+0.92), IBB: 303.35 (-1.27)

Fed's Patience Puts Bulls In A Hurry
Scott Martindale - Seeking Alpha - Tue Dec 23, 11:08AM CST
U.S. stocks found support once again last week and rallied on strong volume. Of course, the main catalyst was the FOMC policy statement on Wednesday that maintained its dovish language with a pledge of considerable time before raising the fed funds...
DEF: 37.72 (-0.43), NFO: 49.06 (-0.27), PNW: 68.31 (-1.09), UTHR: 129.49 (-1.31), ED: 66.01 (-0.90), IBB: 303.35 (-1.27), LUV: 42.32 (+0.15), IYZ: 29.28 (-0.27), LYB: 79.39 (-1.21), SPY: 205.54 (-2.06), IDU: 118.27 (-2.31), IYW: 104.40 (-1.19), IYK: 104.76 (-1.07), IYJ: 106.59 (-1.18), IYH: 144.13 (-1.56), BCR: 166.62 (-2.04), IYM: 82.47 (-0.83), IYC: 137.76 (-0.63), NXPI: 76.40 (+0.82), FUTY: 30.56 (-0.53), IYF: 90.20 (-1.06), IYE: 44.81 (-0.34), PYZ: 52.50 (-0.56), SHW: 263.04 (-1.89), KNOW: 69.11 (-0.63)

Gilead Falls on AbbVie and Express Scripts Deal: 3 Biotech ETFs to Watch - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 11:02AM CST
Gilead shares fell more than 10 percent in Monday trading following news that AbbVie and Express Scripts signed an exclusive Hepatitis C.
PBE: 50.20 (-0.07), ESRX: 84.67 (-1.08), GILD: 94.26 (-1.02), IBB: 303.35 (-1.27), BBH: 115.38 (-0.56), ABBV: 65.44 (-0.86)

Money flowing out of biotech today
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:40AM CST

BIS: 46.00 (+0.17), ESRX: 84.67 (-1.08), GILD: 94.26 (-1.02), BIB: 125.50 (-0.93), IBB: 303.35 (-1.27), ABBV: 65.44 (-0.86)

Inside the Two New Innovative Biotech ETFs from BioShares - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:02AM CST
Two interesting ETFs hit the market from BioShares targeting Clinical Trials and Biotechnology Products.
BBP: 26.12 (-0.06), BBC: 27.74 (+0.25), FBT: 102.02 (-0.42), XBI: 186.46 (+0.92), IBB: 303.35 (-1.27)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 3

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
Global Movement Urges Dr. Hak Ja Han's Release

Updated Category News Views 3

Under the shadows of Manhattan's skyline, something more than a regular service took shape. The New Yorker Hotel hosted an impassioned gathering of the Family Federation for World Peace and Unification. These folks weren't just saying their prayers; they were making a call—loud and resonant—for the release of Dr. Hak Ja Han. The Power of Collective Voices Gathering in...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 2

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
Hims & Hers Faces Class Action: Investors Beware

Updated Category News Views 2

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

Continue Reading
XiamenAir Takes Off with Fujian-London Link

Updated Category News Views 1

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 3

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Roborock Fuels Market Surge with 27.6% Revenue Boost

Updated Category News Views 2

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...

Continue Reading
Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Updated Category News Views 2

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

Continue Reading
FDI Launches 'Generation Smile' for Global Oral Health

Updated Category News Views 4

A New Kind of Movement Imagine a campaign not bound by age or geography but united by a shared mission. Generation Smile, freshly launched by the FDI World Dental Federation in Prague, is just that kind of uprising. This initiative redefines existing approaches to oral health, pushing beyond the boundaries of mere dental care to emphasize the integral role oral health...

Continue Reading
Ice-Rock Avalanches: Future Risks and Urgent Lessons

Updated Category News Views 1

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growing Lab Automation Industry Potential

Updated Category News Views 145

The New Landscape of Lab Automation Recent studies have shown that the global lab automation market is witnessing remarkable growth, driven by advancements in technology, changes in regulatory standards, and increasing demands for efficiency and productivity. As laboratories aim to enhance their operational effectiveness and adapt to ever-evolving scientific needs, the...

Continue Reading
Amazon's Prominence in Retail: A Comparative Analysis

Updated Category News Views 254

Amazon's Competitive Edge in Retail In today's ever-evolving retail landscape, understanding a company's place in the market is vital for both investors and those interested in the business dynamics. This analysis delves into Amazon.com Inc (NASDAQ: AMZN) and offers valuable insights into its performance compared to major competitors within the Broadline Retail sector,...

Continue Reading
Expert Insights on Bitcoin Price Dynamics Amidst Surges

Updated Category News Views 97

Expert Insights on Bitcoin Price Dynamics Bitcoin (BTC) has been in the spotlight lately, especially after it surged to an impressive peak of around $58,487 during Thursday's trading session. However, this significant rise has caught the attention of many industry experts, leading one notable crypto analyst to issue some cautious advice. Julio Moreno, the Head of Research...

Continue Reading
Key Developments in Solid-State Battery Technology by Sunrise

Updated Category News Views 228

Innovative Breakthroughs in Battery Technology In an exciting new development, Sunrise New Energy Co., Ltd. (NASDAQ: EPOW) has taken a significant leap forward in the field of battery technology. Their subsidiary, Sunrise (Guizhou) New Energy Materials Co., Ltd., has collaborated with Songci Electromechanical Technology Co., Ltd. to create an advanced CVD fluidized bed...

Continue Reading
V2X Reports Strong First Quarter and Confirms Annual Goals

Updated Category News Views 135

V2X Reports Strong Results for First Quarter V2X, Inc. (NYSE: VVX) recently unveiled its financial results for the first quarter, demonstrating strong performance with a revenue of $1.02 billion, marking a 10% increase year-over-year, particularly in key markets. The company's commitment to its mission continues to position it effectively within the defense and technology...

Continue Reading